查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800880

脑膜炎双球菌疫苗市场报告（按疫苗类型、成分、疫苗血清型、配销通路、最终用户和地区）2025 年至 2033 年

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球脑膜炎双球菌疫苗市场规模达39亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到76亿美元，2025-2033年期间的复合年增长率（CAGR）为7.3%。日益加重的脑膜炎球菌疾病负担、政府的免疫接种计划、持续的技术进步以及全球卫生安全担忧是推动市场成长的主要动力。

脑膜炎双球菌疫苗市场趋势：

脑膜炎球菌病患疾病率上升

脑膜炎球菌病患病率的上升是推动脑膜炎球菌疫苗需求的重要因素。例如，根据世界卫生组织 (WHO) 的数据，2022 年 11 月至 2023 年 1 月，尼日尔东南部津德尔地区记录了约 559 例脑膜炎病例，其中 18 例死亡；而 2021 年 11 月至 2022 年 1 月报告的病例为 231 例。脑膜炎球菌疾病是由脑膜炎奈瑟菌引起，由于其发病迅速、病情严重且易爆发，仍是全球重大健康问题。高疾病负担推动了对有效疫苗的需求。预计这些因素将在未来几年推动脑膜炎双球菌疫苗市场的发展。

提高认识计划

公共卫生运动、医疗保健提供者教育以及社区外展工作提高了人们对脑膜炎球菌疾病和疫苗接种重要性的认识。例如，葛兰素史克于2021年8月推出了「Ask2BSure」公共卫生运动，鼓励家长咨询孩子的医生，确认是否接种了乙型脑膜炎疫苗。脑膜炎球菌疾病（通常称为脑膜炎）是一种罕见但可能致命的疾病。加深对脑膜炎球菌疾病的了解有助于促进疫苗的接受和推广。这些因素进一步对脑膜炎双球菌疫苗市场预测产生了正面影响。

政府免疫计划

许多国家已製定了常规免疫接种计划，其中包括婴儿、青少年和高风险族群的脑膜炎双球菌疫苗。例如，根据西澳大利亚州政府卫生部2022年11月的更新，学校免疫计画 (SBIP) 将从2023年开始为学生提供白喉-破伤风-百日咳疫苗 (dTpa)、HPV（人类乳突病毒）和脑膜炎双球菌ACWY疫苗。同样，2023年8月，昆士兰州政府计划在未来三年投资9000万美元，为幼儿和成人免费提供脑膜炎球菌B疫苗接种，从而提升脑膜炎球菌疫苗系统市场的收入。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球脑膜炎双球菌疫苗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依疫苗类型

  • 共轭
  • 多醣
  • 包膜下

第七章：市场区隔：依构成

  • 单药疫苗
  • 联合疫苗

第八章：市场区隔：依疫苗血清型

  • 男子ACWY
  • MenB 和 Manic
  • 门氏
  • 男性不孕
  • 门阿克
  • 其他的

第九章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 机构销售
  • 其他的

第十章：市场区隔：依最终用户

  • 儿科
  • 成人

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 12 章：SWOT 分析

第 13 章：价值链分析

第 14 章：波特五力分析

第 15 章：价格分析

第 16 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • GlaxoSmithKline Plc
    • Hualan Biological Engineering Inc.
    • Incepta Pharmaceuticals Limited
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Ltd.
    • Walvax Biotechnology Co. Ltd.
Product Code: SR112025A2730

The global meningococcal vaccines market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The increasing burden of meningococcal disease, government immunization programs, ongoing technological advancements, and global health security concerns are driving the primarily driving the market growth.

Meningococcal Vaccines Market Trends:

Rising Prevalence of Meningococcal Disease

The rising prevalence of meningococcal disease is a significant factor driving the demand for meningococcal vaccines. For instance, according to the World Health Organization (WHO), from November 2022 to January 2023, around 559 cases of meningitis, including 18 deaths, were recorded from Zinder Region, southeast of Niger, compared to 231 cases reported from November 2021 to January 2022. Meningococcal disease, caused by Neisseria meningitidis bacteria, remains a significant global health concern due to its potential for rapid onset, severity, and outbreaks. The high disease burden drives the demand for effective vaccines. These factors are expected to propel the meningococcal vaccines market in the coming years.

Increasing Awareness Programs

Public health campaigns, healthcare provider education, and community outreach efforts have increased awareness about meningococcal disease and the importance of vaccination. For instance, in August 2021, GSK introduced "Ask2BSure," a public health campaign to encourage parents to check with their child's doctor to see if they have meningitis B immunization. Meningococcal disease, often known as meningitis, is a rare but potentially fatal condition. Enhanced understanding promotes vaccine acceptance and uptake. These factors further positively influence the meningococcal vaccines market forecast.

Government Immunization Programs

Many countries have established routine immunization schedules that include meningococcal vaccines, targeting infants, adolescents, and high-risk groups. For example, according to a November 2022 update from the Government of Western Australia Department of Health, the School-Based Immunization Program (SBIP) would provide Diphtheria-tetanus-pertussis (dTpa), HPV (human papillomavirus), and Meningococcal ACWY vaccines to students beginning 2023. Similarly, in August 2023, the Queensland Government planned to invest US$ 90 million over the next three years to offer free meningococcal B vaccine vaccinations for young children and adults, thereby boosting the meningococcal vaccine systems market revenue.

Global Meningococcal Vaccines Industry Segmentation:

Breakup by Vaccine Type:

  • Conjugate
  • Polysaccharide
  • Subcapsular

According to the meningococcal vaccines market outlook, conjugate vaccines are composed of polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, chemically linked (conjugated) to a carrier protein. While polysaccharide vaccines contain purified polysaccharide antigens derived from the bacterial capsule of Neisseria meningitidis. Moreover, subcapsular vaccines target specific surface proteins or antigens located within the bacterial capsule or outer membrane of Neisseria meningitidis.

Breakup by Composition:

  • Mono Vaccines
  • Combination Vaccines

According to the meningococcal vaccines market overview, monovalent vaccines are often in demand during outbreaks or localized epidemics caused by specific meningococcal serogroup. Public health authorities may deploy monovalent vaccines to quickly contain outbreaks and prevent further spread of the disease. While combination vaccines that protect against multiple meningococcal serogroups (e.g., MenACWY) are favored for routine immunization schedules. They streamline vaccination programs by reducing the number of injections and clinic visits required to achieve comprehensive protection.

Breakup by Vaccine Serotype:

  • MenACWY
  • MenB & Manic
  • MenC
  • MenA
  • MenAC
  • Others

MenACWY vaccines protect against meningococcal serogroups A, C, W, and Y. While MenB vaccines target meningococcal serogroup B. MenB vaccines are typically recombinant protein-based or outer membrane vesicle (OMV) vaccines. They contain antigens specific to serogroup B, which are distinct in structure from serogroups A, C, W, and Y. Moreover, MenAC vaccines target meningococcal serogroups A and C. Apart from this, MenA vaccines specifically target meningococcal serogroup A. These are typically monovalent vaccines containing polysaccharide antigens from serogroup A Neisseria meningitidis. Furthermore, MenACWY-DT vaccines combine antigens from meningococcal serogroups A, C, W, and Y.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Hospitals often administer meningococcal vaccines to patients admitted for various reasons, including those at higher risk of contracting meningococcal disease due to immunocompromised status or underlying conditions. Hospital pharmacies may provide vaccinations to individuals requiring preventive care or as part of travel medicine services. While retail pharmacies cater to the general public, offering convenient access to meningococcal vaccines for individuals seeking preventive healthcare. Apart from this, institutional sales involve large-scale procurement of meningococcal vaccines for public health programs, such as national immunization schedules targeting specific age groups or high-risk populations.

Breakup by End User:

  • Pediatric
  • Adult

Meningococcal vaccines, such as MenACWY, are included in routine childhood immunization schedules in many countries. Vaccination typically begins in infancy and continues through childhood, with doses administered according to national guidelines. While young adults who missed meningococcal vaccination during adolescence may receive catch-up doses, especially before entering college or university. College and university dormitories often require proof of meningococcal vaccination, boosting demand among this age group.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the meningococcal vaccines market statistics, the rising prevalence of meningococcal disease in North America is a primary driver. Meningococcal infections can lead to severe outcomes, including meningitis and sepsis, which have spurred vaccination efforts. While stringent healthcare policies and regulations in Europe support the adoption and inclusion of meningococcal vaccines in national immunization schedules. This regulatory environment provides stability and encourages vaccine development and distribution. Apart from this, the Asia Pacific region has seen an increase in the incidence of meningococcal disease, prompting higher demand for vaccines.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Ltd.
  • Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report

  • How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global meningococcal vaccines market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the composition?
  • What is the breakup of the market based on the vaccine serotype?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global meningococcal vaccines market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Meningococcal Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Conjugate
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polysaccharide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subcapsular
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Composition

  • 7.1 Mono Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combination Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Vaccine Serotype

  • 8.1 MenACWY
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 MenB & Manic
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 MenC
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 MenA
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 MenAC
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Institutional Sales
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Pediatric
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Adult
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 GlaxoSmithKline Plc
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Hualan Biological Engineering Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Incepta Pharmaceuticals Limited
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Novartis AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Pfizer Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Sanofi S.A.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Serum Institute of India Ltd.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Walvax Biotechnology Co. Ltd.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials

List of Figures

  • Figure 1: Global: Meningococcal Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Meningococcal Vaccines Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Meningococcal Vaccines Market: Breakup by Vaccine Type (in %), 2024
  • Figure 4: Global: Meningococcal Vaccines Market: Breakup by Composition (in %), 2024
  • Figure 5: Global: Meningococcal Vaccines Market: Breakup by Vaccine Serotype (in %), 2024
  • Figure 6: Global: Meningococcal Vaccines Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Meningococcal Vaccines Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Meningococcal Vaccines Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Meningococcal Vaccines Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 10: Global: Meningococcal Vaccines (Conjugate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Meningococcal Vaccines (Conjugate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Meningococcal Vaccines (Polysaccharide) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Meningococcal Vaccines (Polysaccharide) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Meningococcal Vaccines (Subcapsular) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Meningococcal Vaccines (Subcapsular) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Meningococcal Vaccines (Mono Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Meningococcal Vaccines (Mono Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Meningococcal Vaccines (Combination Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Meningococcal Vaccines (Combination Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Meningococcal Vaccines (MenACWY) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Meningococcal Vaccines (MenACWY) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Meningococcal Vaccines (MenB & Manic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Meningococcal Vaccines (MenB & Manic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Meningococcal Vaccines (MenC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Meningococcal Vaccines (MenC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Meningococcal Vaccines (MenA) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Meningococcal Vaccines (MenA) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Meningococcal Vaccines (MenAC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Meningococcal Vaccines (MenAC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Meningococcal Vaccines (Other Vaccine Serotypes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Meningococcal Vaccines (Other Vaccine Serotypes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Meningococcal Vaccines (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Meningococcal Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Meningococcal Vaccines (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Meningococcal Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Meningococcal Vaccines (Institutional Sales) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Meningococcal Vaccines (Institutional Sales) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Meningococcal Vaccines (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Meningococcal Vaccines (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Meningococcal Vaccines (Pediatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Meningococcal Vaccines (Pediatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Meningococcal Vaccines (Adult) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Meningococcal Vaccines (Adult) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: North America: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: North America: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: United States: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: United States: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Canada: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Canada: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Asia Pacific: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Asia Pacific: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: China: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: China: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Japan: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Japan: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: India: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: India: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: South Korea: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: South Korea: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Australia: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Australia: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Indonesia: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Indonesia: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Europe: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Europe: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Germany: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Germany: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: France: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: France: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: United Kingdom: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: United Kingdom: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Italy: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Italy: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Spain: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Spain: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Russia: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Russia: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Latin America: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Latin America: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Brazil: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Brazil: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Mexico: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Mexico: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Others: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Middle East and Africa: Meningococcal Vaccines Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Middle East and Africa: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Global: Meningococcal Vaccines Industry: SWOT Analysis
  • Figure 93: Global: Meningococcal Vaccines Industry: Value Chain Analysis
  • Figure 94: Global: Meningococcal Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Meningococcal Vaccines Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Meningococcal Vaccines Market Forecast: Breakup by Vaccine Type (in Million USD), 2025-2033
  • Table 3: Global: Meningococcal Vaccines Market Forecast: Breakup by Composition (in Million USD), 2025-2033
  • Table 4: Global: Meningococcal Vaccines Market Forecast: Breakup by Vaccine Serotype (in Million USD), 2025-2033
  • Table 5: Global: Meningococcal Vaccines Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Meningococcal Vaccines Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 7: Global: Meningococcal Vaccines Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Meningococcal Vaccines Market: Competitive Structure
  • Table 9: Global: Meningococcal Vaccines Market: Key Players